Top Health-care stocks:
Health care shares were mostly unchanged in pre-market trade Thursday.
In health care stocks news, Aradigm ( ARDM ) was 63.4% higher in pre-market trade, coming off a trading halt, after the company reported mixed top-line results from two phase 3 studies of Pulmaquin for patients with non-cystic fibrosis bronchiectasis with chronic lung infections with Pseudomonas aeruginosa. In the ORBIT-3 trial, the median time to first, mild or severe pulmonary exacerbation was 221 days in the treatment group compared to 126 in the placebo group but was not statistically significant. In the key secondary efficacy endpoint, there was a 13% reduction in the frequency of PE's over the 48-week treatment period in the Pulmaquin treatment group as compared to the placebo group.
And, Heat Biologics ( HTBX ) was down 51.9% after the company reported data from its phase 2 trial of HS-410 for the treatment of non-muscle invasive bladder cancer showed that the vaccine did not generate a statistically significant difference in the primary endpoint compared with placebo.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
Copyright (C) 2016 MTNewswires.com. All rights reserved. Unauthorized reproduction is strictly prohibited.